<DOC>
	<DOCNO>NCT02043132</DOCNO>
	<brief_summary>To Investigators ' knowledge , TXA study set reverse total shoulder arthroplasty . We propose double-blinded , randomize , control trial compare perioperative administration TXA placebo set RTSA . The purpose study examine efficacy TXA reduce overall blood loss transfusion rate patient undergoing reverse total shoulder arthroplasty .</brief_summary>
	<brief_title>Tranexamic Acid Reverse Total Shoulder Arthroplasty</brief_title>
	<detailed_description>Shoulder arthroplasty procedure use relieve pain dysfunction associate arthritic destruction gleno-humeral joint . It demonstrate patient concomitant rotator cuff deficiency , reverse total shoulder arthroplasty ( rTSA ) efficacious procedure relieve pain well increase lever-arm deltoid muscle , thus improve post-operative strength range motion . However , perioperative blood loss total shoulder arthroplasty significant , overall rate allogeneic blood transfusion report 7.4 % -43 % [ 1-5 ] . Patients undergo reverse total shoulder arthroplasty even risk require postoperative blood transfusion [ 2 ] . Blood transfusion associate significant risk patient health range mild life threaten . Tranexamic acid ( TXA ) antifibrinolytic medication ( reduces destruction blood clot , thus promote ability stop bleeding ) frequently use reduce perioperative blood loss , blood transfusion associate cost major cardiac , vascular , obstetric , orthopedic procedure . Currently , TXA increasingly use orthopedic joint reconstructive surgery proven safe effective reduce blood loss follow total knee arthroplasty ( TKA ) total hip arthroplasty ( THA ) [ 11-33 ] . Multiple recent meta-analyses find use TXA set TKA THA lead significantly less overall blood loss lower rate blood transfusion without increase rate venous thromboembolism ( VTE ) complication [ 34-37 ] . TXA formulary William Beaumont Hospital . 100 patient slat undergo elective reverse total shoulder arthroplasty recruit randomized receive either infusion standard dose TXA ( 10mg/kg ) placebo ( equivalent volume normal saline ) within 60 minute prior surgery wound closure . Adult subject 18 year age old participate study objective , method , potential hazard study fully explain , sign informed consent form . The Investigator designee responsible keep record subject sign inform consent form entry study DATA AND SAFETY MONITORING PLAN Beaumont Research follow standard operating policy procedure establish group designate Beaumont Hospital faculty responsible data safety monitoring . This group include clinician , physician , scientific member statistician . They meet twice throughout course study . A medical monitor appoint since single-site study ; Dr. J. Michael Wiater personally oversee health well-being patient submit AE report , designate group directly review adverse event report . Beaumont 's Human Investigation Committee review data safety monitoring plan part IRB approval process . Study data transcribed study personnel source document electronic database maintain Excel . The data collection form complete research nurse time data collection always reflect late observation subject participate study . Demographic data fill preoperatively , intraoperative blood loss record OR , postoperative blood loss transfusion collect retrospectively , complication record occur 2 6 week follow-up . All data entry , correction alteration must make investigator authorized study personnel . The Research Institute complete internal auditing random interval study data integrity , proper inform consent process implementation documentation , protocol adherence , patient safety reporting compliance regulatory body . Descriptive statistic provide data collect . Missing data remain miss replace substitution interpolation . Statistical software ( SPSS , IBM , Inc ) use analysis . Baseline demographic data compare 2 randomization arm determine imbalance exist . Categorical variable show count % frequency . They examine use Pearson 's Chi-square appropriate ( expect frequency &gt; 5 ) , otherwise Fisher 's Exact test use . Continuous variable examine normality . Normally distributed variable analyze use t-tests non-normally distributed variable examine use non-parametric Wilcoxon rank test . All continuous variable show means+/- standard deviation follow median ( 25th , 75th percentile ) need . The primary outcome intraoperative postoperative blood loss postoperative drop Hb examine normality . Normally distributed variable analyze use t-tests non-normally distributed variable examine use non-parametric Wilcoxon rank test . Total number postoperative transfusion total number patient require postoperative transfusion show count % frequency . They examine use Pearson 's Chi-square appropriate ( expect frequency &gt; 5 ) , otherwise Fisher 's Exact test use . The secondary outcome systemic surgical site complication examine two randomization arm use Pearson 's Chi-square appropriate ( expect frequency &gt; 5 ) , otherwise Fisher 's Exact test use .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Intraoperative Complications</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Antifibrinolytic Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Patients undergo schedule primary reverse total shoulder arthroplasty perform J. Michael Wiater , MD . 2 . Patients age 18 old 1 . Pregnant* breastfeed woman 2 . Allergy tranexamic acid 3 . Acquired disturbance color vision 4 . Use estrogen contain medication ( i.e . oral contraceptive pill ) 5 . Hormone replacement therapy 6 . Preoperative anemia [ Hemoglobin ( Hb ) &lt; 11g/dL female , Hb &lt; 12 g/dL male ] 7 . Refusal blood product 8 . Preoperative use anticoagulant therapy within 5 day prior surgery 1 . Coumadin 2 . Heparin 3 . Low molecular weight heparin 4 . Factor Xa inhibitor 9 . Thrombin inhibitor 10 . Coagulopathy 11 . Thrombophilia 12 . Antithrombin deficiency 13 . Factor V Leiden 14 . Antiphospholipid Syndrome 15 . Protein C S deficiency 16 . History heparin induce thrombocytopenia 17 . Sickle cell anemia 18 . Myeloproliferative disorder 19 . Platelet &lt; 150,00 mm3 20. International Normalized Ratio ( INR ) &gt; 1.4 21 . Partial Thromboplastin Time ( PTT ) &gt; 1.4 time normal 22 . A history arterial venous thromboembolism 23 . Cerebral Vascular Accident 24 . Deep Vein Thrombosis 25 . Pulmonary Embolism 26 . Subarachnoid hemorrhage 27 . Active intravascular clot 28 . Major comorbidities 29 . Coronary artery disease ( New York Heart Association Class III IV ) 30 . Previous MI 31 . Severe pulmonary disease ( FEV &lt; 50 % normal ) 32 . Plasma creatinine &gt; 115 μmol/L male , &gt; 100 μmol/L female , hepatic failure ) 34 . Participation another clinical trial 35 . *All woman child bear potential must negative serum urine pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>reverse shoulder arthroplasty</keyword>
	<keyword>Rotator cuff</keyword>
	<keyword>Orthopedic joint surgery</keyword>
	<keyword>Total shoulder</keyword>
	<keyword>Perioperative bleeding</keyword>
	<keyword>Tranexamic acid</keyword>
	<keyword>Orthopedic complication</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>Postoperative Hemorrhage</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Postoperative Complications</keyword>
	<keyword>Antifibrinolytic Agents</keyword>
	<keyword>Fibrin Modulating Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Hemostatics</keyword>
	<keyword>Coagulants</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>